Prostate Cancer Centre | Calgary, Canada

Research site

(Unclaimed)

Location

7007 14 Street SW, Suite 6500, Calgary, Alberta, Canada

Site insights

Top conditions

Top treatments

Darolutamide

Enzalutamide

Apalutamide

Abiraterone Acetate

Prednisone

Leuprolide

BAY1841788

Talazoparib

Androgen

Niraparib

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 14 total trials

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy (PROTEUS)

The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectom...

Active, not recruiting

Prostatic Neoplasms

Drug: Placebo

Drug: Apalutamide

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (AMPLITUDE)

The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus predniso...

Active, not recruiting

Metastatic Castration-sensitive Prostate Cancer

Drug: Niraparib

Drug: Prednisone

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP)

Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer.BCR means that in men who had p...

Enrolling

Biochemically Recurrent Prostate Cancer

Other: Placebo matching darolutamide

Drug: Darolutamide (BAY1841788, Nubeqa)

EPI-7386 in Combination With Enzalutamide Compared With Enzalutamide Alone in Subjects With mCRPC

This is a Phase 1/2 study of EPI-7386 orally administered in combination with enzalutamide in subjects with mCRPC.Phase 1 of the study will be a sing...

Enrolling

Prostate Cancer

Drug: Enzalutamide

Drug: EPI-7386 with Enzalutamide

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

The purpose of this study is to assess enzalutamide plus leuprolide in patients with high-risk nonmetastatic prostate cancer progressing after radica...

Active, not recruiting

Hormone Sensitive Prostate Cancer

Prostate Cancer

Drug: Enzalutamide

Drug: Leuprolide Open Label

Locations recently updated

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination...

Active, not recruiting

Prostate Cancer

Drug: Placebo plus enzalutamide

Drug: talazoparib plus enzalutamide

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and...

Enrolling

Cancer

Drug: Darolutamide (Nubeqa, BAY1841788)

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms